Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Hypothalamic Obesity
NCT04725240Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of setmelanotide in hypothalamic obesity (HO), sponsored by Rhythm Pharmaceuticals. Started Jun 2021; status: completed.
02
Drugs
setmelanotide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT04725240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725240.